| NCT Number | NCT05023551 |
| Lead Sponsor | Sumitomo Pharma America, Inc. |
| Conditions | High Grade Glioma, Glioblastoma Multiforme |
| Enrollment | 39 participants |
| Start Date | 2021-09-08 |
| Primary Completion | 2027-09-30 (estimated) |
| Study Completion | 2027-10-31 (estimated) |
| Updated on ClinicalTrials.gov | 2026-07-29 |